1. Market Research
  2. > Healthcare
  3. > Health Facility Market Trends
  4. > CRO Quality Benchmarking Phase I Service Providers (6th edition)

CRO Quality Benchmarking Phase I Service Providers (6th edition)

  • May 2014
  • -
  • Industry Standard Research
  • -
  • 151 pages

Summary

Table of Contents

This research, based on in-depth surveys collected from 113 pharmaceutical Phase I decision-makers, indicates that SGS Life Sciences out-performs customers’ expectations across a number of critical delivery drivers.

“Loyalty in the clinical research services industry is extraordinarily difficult to achieve,” explained Kevin Olson, CEO of Industry Standard Research. “The challenges associated with professional services industries and other highly regulated industries tend to lead to little differentiation among service providers. While SGS was not the only strong performer, their leadership across many Staff, Operational Excellence, and Financial factors place them in a very strong position,” Olson continued.

The 2014 CRO Quality Benchmarking – Phase I Service Providers report is a comprehensive, Consumer Reports-style assessment of Phase I service providers that captures buyers’ experiences from around the globe. It provides Phase I delivery quality data for the following 27 CROs:

• Biotrial
• CEDRA
• Celerion
• CHDR
• Chiltern
• Clinical Research Services (CRS)
• Covance
• DaVita
• DCRI-Duke
• Frontage
• HungaroTrial
• ICON
• INC Research
• inVentiv Health Clinical
• Medpace
• PAREXEL
• PPD
• PRA
• Premier Research
• Quintiles
• Quotient Clinical
• Rho
• SGS Life Sciences
• Siro Clinpharm
• Theorem
• US Oncology
• WCCT Global

The report provides delivery quality data across the following 27 dimensions:

Staff Characteristics

• Experience of the Phase I unit’s lead investigator
• Minimizing staff turnover
• Project manager quality
• Project team chemistry
• Responsiveness
• Scientific knowledge
• Therapeutic expertise

Operational Excellence

• Data quality
• Local market / Regulatory knowledge
• Meeting database lock timelines
• Meeting first patient / first visit timelines
• Meeting overall project timelines
• Offered innovative solutions
• Patient / volunteer recruitment
• Speed of site start-up
• Technology for real-time access to data
• Timely project communications
• Up-front contingency planning, risk management

Organizational & Finance Characteristics

• Access to “unique” tests, machines, equipment
• Access to a broad range of services beyond clinic / volunteer management
• Access to patient populations
• Financial strength / stability
• Location of Phase I unit(s) in different global regions
• Location of Phase I unit(s) within your country
• Low cost
• Minimizing change orders
• Timely access to open bed / clinic space

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 Analysis of the Global Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

2017 Analysis of the Global Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

  • $ 28500
  • Industry report
  • March 2017
  • by Venture Planning Group

Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during the next ten years- Examines trends in the U.S., Europe and Japan- Reviews current and emerging ...

2017-2021 World Tumor Marker Testing Market: Global Opportunities and Growth Strategies for Suppliers

2017-2021 World Tumor Marker Testing Market: Global Opportunities and Growth Strategies for Suppliers

  • $ 21100
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...

2017 Competing in the Global Cancer Diagnostics Market

2017 Competing in the Global Cancer Diagnostics Market

  • $ 21100
  • Industry report
  • March 2017
  • by Venture Planning Group

This new VPGMarketResearch.com comprehensive seven-country study identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.